http://rdf.ncbi.nlm.nih.gov/pubchem/patent/HU-0500617-A2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_69ece09bafee7e0c49d1f7951a3faa2c |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6803 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57492 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-395 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-53 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-68 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-577 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12P21-08 |
| filingDate | 2002-09-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e35e8ea3d0cfe09e50770929cfc1e9be |
| publicationDate | 2005-10-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | HU-0500617-A2 |
| titleOfInvention | Methods for identifying polypeptide antigens associated with irregular cell proliferation disorders and compositions for treating such disorders |
| abstract | The present invention provides methods and compositions for developing effective cancer therapies using mitotic inhibitors that exhibit limited overall toxicity to normal, non-cancerous cells and tissues. The methods and compositions of the present invention use cytotoxic compounds comprising a cell binding agent (e.g., an antibody) conjugated to an anti-mitotic compound (e.g., a maytansinoid). The invention further provides antibodies that are substantially incapable of inducing antibody-dependent cell-mediated cytotoxicity (ADCC) or complement-dependent cytotoxicity (CDC), ensuring that the therapeutic effect is mediated primarily by the mitotic inhibitor component of the cytotoxic compound and not by the ADCC and / or CDC response. mediated indirect cell death. The antibodies of the invention are able to distinguish polypeptide antigens that are expressed at higher levels in proliferating cancer cells than in proliferating non-cancerous cells. |
| priorityDate | 2001-09-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 1084.